The effects of rosiglitazone on myocardial triglyceride content in patients with type 2 diabetes: A randomised, placebo-controlled trial

Diabetes and Vascular Disease Research

Volumn 9, Issue 2, 2012, Pages 131-137

  McGavock, Jonathan ^a,b,c   Szczepaniak, Lidia S ^d   Ayers, Colby R ^b   Abdullah, Shuaib M ^a,b   See, Raphael ^a,b,e   Odette Gore, M ^a,b   Drazner, Mark H ^a,b   De Lemos, James A ^a,b   McGuire, Darren K ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c MANITOBA INSTITUTE OF CHILD HEALTH   (Canada)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e VANDERBILT UNIVERSITY   (United States)

Author keywords

Lipotoxicity; MRI; Steatosis; Thiazolidinedione

Indexed keywords

PLACEBO; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFECT; FEMALE; HEART LEFT VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

AGED; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MYOCARDIUM; PLACEBOS; PREVALENCE; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE VOLUME; TEXAS; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; VENTRICULAR FUNCTION, LEFT;

EID: 84861038555     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164111428628     Document Type: Article

References (30)

1. McGavock JM, Lingvay I, Zib I, et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopystudy. Circulation 2007; 116: 1170-1175. (Pubitemid 47360218)
2. McGavock JM, Victor RG, Unger RH and Szczepaniak LS. Adiposity of the heart, revisited. Ann Intern Med 2006; 144: 517-524. (Pubitemid 46780675)
3. Rijzewijk LJ, van der Meer RW, Smit JW, et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol 2008; 52:1793-1799.
4. Sharma S, Adrogue JV, Golfman L, et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J 2004; 18: 1692-1700. (Pubitemid 39463708)
5. Saunders J, Mathewkutty S, Drazner MH and McGuire DK. Cardiomyopathy in type 2 diabetes: update on pathophysiological mechanisms. Herz 2008; 33: 184-190. (Pubitemid 351581153)
6. Zhou YT, Grayburn P, Karim A, et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A 2000; 97: 1784-1789. (Pubitemid 30118520)
7. Yue TL, Bao W, Gu JL, et al. Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion- induced myocardial injury. Diabetes 2005; 54: 554-562.
8. Muurling M, Mensink RP, Pijl H, Romijn JA, Havekes LM and Voshol PJ. Rosiglitazone improves muscle insulin sensitivity,irrespective of increased triglyceride content, in ob/ob mice. Metabolism 2003; 52: 1078-1083. (Pubitemid 37098381)
9. Nissen SE and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascularcauses. N Engl J Med 2007; 356: 2457-2471. (Pubitemid 46919772)
10. McGuire DK and Inzucchi SE. New drugs for the treatment of diabetes mellitus: part I: Thiazolidinediones and their evolving cardiovascular implications. Circulation 2008;117: 440-449.
11. McGuire DK, Abdullah SM, See R, et al. Randomized comparison of the effects of rosiglitazone vs. placebo on peakintegrated cardiovascular performance, cardiac structure, and function. Eur Heart J 2010; 31: 2262-2270.
12. McGuire DK, See R, Abdullah SM, et al. The effect of rosiglitazone on integrated cardiovascular performance,cardiac structure, function and myocardial triglyceride: trial design and rationale. Diab Vasc Dis Res 2009; 6: 43-50.
13. American Diabetes Association. Standards of medical care in diabetes - 2010. Diabetes Care 2010; 33 Suppl 1: S11-61.
14. McGavock JM, Hastings JL, Snell PG, et al. A forty-year follow- up of the Dallas Bed Rest and Training study: the effect of age on the cardiovascular response to exercise in men. J Gerontol A Biol Sci Med Sci 2009; 64: 293-299.
15. McGuire DK, Levine BD, Williamson JW, et al. A 30-year follow-up of the Dallas Bedrest and Training Study: I. Effectof age on the cardiovascular response to exercise. Circulation 2001; 104: 1350-1357. (Pubitemid 32880146)
16. Reingold JS, McGavock JM, Kaka S, Tillery T, Victor RG and Szczepaniak LS. Determination of triglyceride in thehuman myocardium by magnetic resonance spectroscopy: reproducibility and sensitivity of the method. Am J Physiol Endocrinol Metab 2005; 289: E935-939. (Pubitemid 41504396)
17. Szczepaniak LS, Dobbins RL, Metzger GJ, et al. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med 2003; 49: 417-423. (Pubitemid 36262808)
18. Drazner MH, Dries DL, Peshock RM, et al. Left ventricular hypertrophy is more prevalent in blacks than whites in thegeneral population: the Dallas Heart Study. Hypertension 2005; 46: 124-129. (Pubitemid 40946502)
19. Chung AK, Das SR, Leonard D, et al. Women have higher left ventricular ejection fractions than men independentof differences in left ventricular volume: the Dallas Heart Study. Circulation 2006; 113: 1597-1604. (Pubitemid 43739419)
20. Zib I, Jacob AN, Lingvay I, et al. Effect of pioglitazone therapyon myocardial and hepatic steatosis in insulin-treated patients with type 2 diabetes. J Investig Med 2007; 55: 230-236. (Pubitemid 47555941)
21. van der Meer RW, Rijzewijk LJ, de Jong HW, et al. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation 2009; 119: 2069-2077.
22. van der Meer RW, Rijzewijk LJ, Diamant M, et al. The ageingmale heart: myocardial triglyceride content as independent predictor of diastolic function. Eur Heart J 2008; 29: 1516-1522. (Pubitemid 351881987)
23. Chiu HC, Kovacs A, Ford DA, et al. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 2001; 107: 813-822. (Pubitemid 32274034)
24. Ng AC, Delgado V, Bertini M, et al. Myocardial steatosis and biventricular strain and strain rate imaging in patients with type 2 diabetes mellitus. Circulation 2010; 122: 2538-2544.
25. Diamant M, Lamb HJ, Groeneveld Y, et al. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type2 diabetes mellitus. J Am Coll Cardiol 2003; 42: 328-335. (Pubitemid 36851426)
26. Harmancey R, Wilson CR and Taegtmeyer H. Adaptation and maladaptation of the heart in obesity. Hypertension 2008; 52: 181-187.
27. Karalliedde J, Buckingham R, Starkie M, Lorand D, Stewart M and Viberti G. Effect of various diuretic treatments on rosiglitazone-induced fluid retention. J Am Soc Nephrol 2006; 17: 3482-3490. (Pubitemid 44865290)
28. Narang N, Armstead SI, Stream A, et al. Assessment of cardiac structure and function in patients without and withperipheral oedema during rosiglitazone treatment. Diab Vasc Dis Res 2011; 8: 101-108.
29. van der Meer RW, Doornbos J, Kozerke S, et al. Metabolic imaging of myocardial triglyceride content: reproducibilityof 1H MR spectroscopy with respiratory navigator gating in volunteers. Radiology 2007; 245: 251-257. (Pubitemid 47417809)
30. Bree D, Wollmuth JR, Cupps BP, et al. Low-dose dobutamine tissue-tagged magnetic resonance imaging with3-dimensional strain analysis allows assessment of myocardial viability in patients with ischemic cardiomyopathy. Circulation 2006; 114: I33-36. (Pubitemid 44297125)